US Stock MarketDetailed Quotes

ESPR Esperion Therapeutics

Watchlist
  • 2.190
  • +0.015+0.69%
Close Dec 20 16:00 ET
  • 2.180
  • -0.010-0.45%
Post 19:56 ET
431.51MMarket Cap-3.27P/E (TTM)

Esperion Therapeutics Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
52.00%51.63M
186.33%73.83M
466.14%137.74M
54.14%116.33M
71.38%32.25M
78.97%33.97M
36.86%25.79M
29.16%24.33M
-3.79%75.48M
22.19%18.82M
Operating revenue
52.00%51.63M
186.33%73.83M
466.14%137.74M
54.14%116.33M
71.38%32.25M
78.97%33.97M
36.86%25.79M
29.16%24.33M
-3.79%75.48M
22.19%18.82M
Cost of revenue
29.22%17.29M
130.02%15.61M
-13.53%10.08M
60.44%43.27M
175.29%11.45M
105.61%13.38M
-26.05%6.79M
63.54%11.65M
89.68%26.97M
-18.03%4.16M
Gross profit
66.79%34.35M
206.45%58.23M
907.02%127.66M
50.63%73.07M
41.89%20.8M
65.08%20.59M
96.59%19M
8.25%12.68M
-24.48%48.51M
41.95%14.66M
Operating expense
4.67%50.37M
-0.73%55.65M
-9.61%55.39M
0.27%228.63M
10.48%63.17M
-11.04%48.13M
-9.64%56.06M
12.03%61.28M
-21.64%228.01M
-13.32%57.17M
Selling and administrative expenses
20.26%39.98M
30.11%44.19M
40.42%41.99M
30.66%142.52M
88.18%45.42M
33.21%33.24M
14.69%33.96M
-1.58%29.9M
-41.03%109.08M
-37.04%24.14M
Research and development costs
-30.15%10.4M
-48.14%11.46M
-57.29%13.4M
-27.60%86.11M
-46.29%17.74M
-48.92%14.89M
-31.86%22.1M
29.04%31.38M
12.22%118.93M
19.62%33.03M
Operating profit
41.79%-16.03M
106.96%2.58M
248.69%72.27M
13.34%-155.56M
0.34%-42.37M
33.85%-27.53M
29.25%-37.06M
-13.06%-48.61M
20.83%-179.5M
23.58%-42.51M
Net non-operating interest income expense
-0.58%-15.08M
5.60%-13.72M
2.52%-14.02M
-3.81%-58.98M
-5.08%-15.06M
-5.95%-15M
-1.90%-14.54M
-2.31%-14.39M
-22.56%-56.81M
-6.69%-14.33M
Non-operating interest expense
0.58%15.08M
-5.60%13.72M
-2.52%14.02M
3.81%58.98M
5.08%15.06M
5.95%15M
1.90%14.54M
2.31%14.39M
22.56%56.81M
6.69%14.33M
Other net income (expense)
23.94%1.58M
-3,159.10%-50.78M
118.15%2.78M
99.51%5.29M
-20.30%1.08M
93.93%1.28M
422.01%1.66M
297.81%1.27M
-33.28%2.65M
-65.60%1.36M
Special income (charges)
--0
---53.24M
----
----
----
--0
--0
----
----
----
-Less:Other special charges
----
--53.24M
----
----
----
----
----
----
----
----
Other non- operating income (expenses)
23.94%1.58M
47.83%2.45M
118.15%2.78M
99.51%5.29M
-20.30%1.08M
93.93%1.28M
422.01%1.66M
297.81%1.27M
-33.28%2.65M
-65.60%1.36M
Income before tax
28.43%-29.52M
-24.01%-61.93M
198.87%61.02M
10.45%-209.25M
-1.54%-56.34M
25.16%-41.25M
24.71%-49.94M
-8.79%-61.72M
13.17%-233.66M
14.79%-55.49M
Income tax
Net income
28.43%-29.52M
-24.01%-61.93M
198.87%61.02M
10.45%-209.25M
-1.54%-56.34M
25.16%-41.25M
24.71%-49.94M
-8.79%-61.72M
13.17%-233.66M
14.79%-55.49M
Net income continuous Operations
28.43%-29.52M
-24.01%-61.93M
198.87%61.02M
10.45%-209.25M
-1.54%-56.34M
25.16%-41.25M
24.71%-49.94M
-8.79%-61.72M
13.17%-233.66M
14.79%-55.49M
Minority interest income
Net income attributable to the parent company
28.43%-29.52M
-24.01%-61.93M
198.87%61.02M
10.45%-209.25M
-1.54%-56.34M
25.16%-41.25M
24.71%-49.94M
-8.79%-61.72M
13.17%-233.66M
14.79%-55.49M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
28.43%-29.52M
-24.01%-61.93M
198.87%61.02M
10.45%-209.25M
-1.54%-56.34M
25.16%-41.25M
24.71%-49.94M
-8.79%-61.72M
13.17%-233.66M
14.79%-55.49M
Basic earnings per share
59.46%-0.15
28.26%-0.33
145.57%0.36
42.33%-2.03
34.21%-0.5
54.32%-0.37
56.19%-0.46
15.05%-0.79
62.19%-3.52
57.06%-0.76
Diluted earnings per share
59.46%-0.15
28.26%-0.33
143.04%0.34
42.33%-2.03
34.21%-0.5
54.32%-0.37
56.19%-0.46
15.05%-0.79
62.19%-3.52
57.06%-0.76
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 52.00%51.63M186.33%73.83M466.14%137.74M54.14%116.33M71.38%32.25M78.97%33.97M36.86%25.79M29.16%24.33M-3.79%75.48M22.19%18.82M
Operating revenue 52.00%51.63M186.33%73.83M466.14%137.74M54.14%116.33M71.38%32.25M78.97%33.97M36.86%25.79M29.16%24.33M-3.79%75.48M22.19%18.82M
Cost of revenue 29.22%17.29M130.02%15.61M-13.53%10.08M60.44%43.27M175.29%11.45M105.61%13.38M-26.05%6.79M63.54%11.65M89.68%26.97M-18.03%4.16M
Gross profit 66.79%34.35M206.45%58.23M907.02%127.66M50.63%73.07M41.89%20.8M65.08%20.59M96.59%19M8.25%12.68M-24.48%48.51M41.95%14.66M
Operating expense 4.67%50.37M-0.73%55.65M-9.61%55.39M0.27%228.63M10.48%63.17M-11.04%48.13M-9.64%56.06M12.03%61.28M-21.64%228.01M-13.32%57.17M
Selling and administrative expenses 20.26%39.98M30.11%44.19M40.42%41.99M30.66%142.52M88.18%45.42M33.21%33.24M14.69%33.96M-1.58%29.9M-41.03%109.08M-37.04%24.14M
Research and development costs -30.15%10.4M-48.14%11.46M-57.29%13.4M-27.60%86.11M-46.29%17.74M-48.92%14.89M-31.86%22.1M29.04%31.38M12.22%118.93M19.62%33.03M
Operating profit 41.79%-16.03M106.96%2.58M248.69%72.27M13.34%-155.56M0.34%-42.37M33.85%-27.53M29.25%-37.06M-13.06%-48.61M20.83%-179.5M23.58%-42.51M
Net non-operating interest income expense -0.58%-15.08M5.60%-13.72M2.52%-14.02M-3.81%-58.98M-5.08%-15.06M-5.95%-15M-1.90%-14.54M-2.31%-14.39M-22.56%-56.81M-6.69%-14.33M
Non-operating interest expense 0.58%15.08M-5.60%13.72M-2.52%14.02M3.81%58.98M5.08%15.06M5.95%15M1.90%14.54M2.31%14.39M22.56%56.81M6.69%14.33M
Other net income (expense) 23.94%1.58M-3,159.10%-50.78M118.15%2.78M99.51%5.29M-20.30%1.08M93.93%1.28M422.01%1.66M297.81%1.27M-33.28%2.65M-65.60%1.36M
Special income (charges) --0---53.24M--------------0--0------------
-Less:Other special charges ------53.24M--------------------------------
Other non- operating income (expenses) 23.94%1.58M47.83%2.45M118.15%2.78M99.51%5.29M-20.30%1.08M93.93%1.28M422.01%1.66M297.81%1.27M-33.28%2.65M-65.60%1.36M
Income before tax 28.43%-29.52M-24.01%-61.93M198.87%61.02M10.45%-209.25M-1.54%-56.34M25.16%-41.25M24.71%-49.94M-8.79%-61.72M13.17%-233.66M14.79%-55.49M
Income tax
Net income 28.43%-29.52M-24.01%-61.93M198.87%61.02M10.45%-209.25M-1.54%-56.34M25.16%-41.25M24.71%-49.94M-8.79%-61.72M13.17%-233.66M14.79%-55.49M
Net income continuous Operations 28.43%-29.52M-24.01%-61.93M198.87%61.02M10.45%-209.25M-1.54%-56.34M25.16%-41.25M24.71%-49.94M-8.79%-61.72M13.17%-233.66M14.79%-55.49M
Minority interest income
Net income attributable to the parent company 28.43%-29.52M-24.01%-61.93M198.87%61.02M10.45%-209.25M-1.54%-56.34M25.16%-41.25M24.71%-49.94M-8.79%-61.72M13.17%-233.66M14.79%-55.49M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 28.43%-29.52M-24.01%-61.93M198.87%61.02M10.45%-209.25M-1.54%-56.34M25.16%-41.25M24.71%-49.94M-8.79%-61.72M13.17%-233.66M14.79%-55.49M
Basic earnings per share 59.46%-0.1528.26%-0.33145.57%0.3642.33%-2.0334.21%-0.554.32%-0.3756.19%-0.4615.05%-0.7962.19%-3.5257.06%-0.76
Diluted earnings per share 59.46%-0.1528.26%-0.33143.04%0.3442.33%-2.0334.21%-0.554.32%-0.3756.19%-0.4615.05%-0.7962.19%-3.5257.06%-0.76
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.